14 October 2024
14 October 2024
The Cardiovascular and Renal Drugs Advisory Committee voted 10-6 in support of Stealth’s elamipretide for the ultra-rare disorder.
Starboard has accused Pfizer of “coercive conduct” after executives who initially backed the hedge fund retracted their support.
At CPHI Europe, Angela Vollstedt, global director of Cell & Gene Therapies at Novartis discussed scale up strategies for cell therapies.
Operating independently within Sanofi, Opella has resources allocated for research and development, production, and digital operations.
HYMPAVZI is the first and only approved anti-tissue factor pathway inhibitor in the US for haemophilia A or B treatment.
The US FDA approved Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex as the first-line treatment for certain breast cancer patients.
High-concentration monoclonal antibodies (mAbs) are gaining prominence given the compliance and cost advantages.
Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report offers a comprehensive insight into the plaque psoriasis market through 2032. The report provides an overview of the disease including epidemiology, symptoms, diagnosis, disease management, countries where the disease is prevalent, and leading players associated with the market. Per our estimates, the market is expected to achieve a CAGR of >10% during 2020-2030 because of the steady increase in total diagnosed prevalent cases across the 7MM.
GlobalData's latest report offers a comprehensive insight into the plaque psoriasis market through 2032. The report provides an overview of the disease including epidemiology, symptoms, diagnosis, disease management, countries where the disease is prevalent, and leading players associated with the market. Per our estimates, the market is expected to achieve a CAGR of >10% during 2020-2030 because of the steady increase in total diagnosed prevalent cases across the 7MM.
Give your business an edge with our leading industry insights.
